These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Effects of adenosine and a selective A2A adenosine receptor agonist on hemodynamic and thallium-201 and technetium-99m-sestaMIBI biodistribution and kinetics. Mekkaoui C; Jadbabaie F; Dione DP; Meoli DF; Purushothaman K; Belardinelli L; Sinusas AJ JACC Cardiovasc Imaging; 2009 Oct; 2(10):1198-208. PubMed ID: 19833310 [TBL] [Abstract][Full Text] [Related]
7. Myocardial perfusion imaging laboratory efficiency with the use of regadenoson compared to adenosine and dipyridamole. Friedman M; Spalding J; Kothari S; Wu Y; Gatt E; Boulanger L J Med Econ; 2013; 16(4):449-60. PubMed ID: 23363331 [TBL] [Abstract][Full Text] [Related]
8. Caffeine attenuates the duration of coronary vasodilation and changes in hemodynamics induced by regadenoson (CVT-3146), a novel adenosine A2A receptor agonist. Zhao G; Messina E; Xu X; Ochoa M; Sun HL; Leung K; Shryock J; Belardinelli L; Hintze TH J Cardiovasc Pharmacol; 2007 Jun; 49(6):369-75. PubMed ID: 17577101 [TBL] [Abstract][Full Text] [Related]
9. Regadenoson: review of its established role in myocardial perfusion imaging and emerging applications. Palani G; Ananthasubramaniam K Cardiol Rev; 2013; 21(1):42-8. PubMed ID: 22643345 [TBL] [Abstract][Full Text] [Related]
10. Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function. Gordi T; Blackburn B; Lieu H J Clin Pharmacol; 2007 Jul; 47(7):825-33. PubMed ID: 17585115 [TBL] [Abstract][Full Text] [Related]
11. [Regadenoson as a new stress agent in myocardial perfusion imaging. Initial experience in The Netherlands]. Jager PL; Buiting M; Mouden M; Oostdijk AH; Timmer J; Knollema S Rev Esp Med Nucl Imagen Mol; 2014; 33(6):346-51. PubMed ID: 24862658 [TBL] [Abstract][Full Text] [Related]
12. Acute myocardial infarction during regadenoson myocardial perfusion imaging. Shah S; Parra D; Rosenstein RS Pharmacotherapy; 2013 Jun; 33(6):e90-5. PubMed ID: 23471769 [TBL] [Abstract][Full Text] [Related]
13. Regadenoson in the detection of coronary artery disease. Buhr C; Gössl M; Erbel R; Eggebrecht H Vasc Health Risk Manag; 2008; 4(2):337-40. PubMed ID: 18561509 [TBL] [Abstract][Full Text] [Related]
14. Regadenoson-stress myocardial CT perfusion and single-photon emission CT: rationale, design, and acquisition methods of a prospective, multicenter, multivendor comparison. Cury RC; Kitt TM; Feaheny K; Akin J; George RT J Cardiovasc Comput Tomogr; 2014; 8(1):2-12. PubMed ID: 24314823 [TBL] [Abstract][Full Text] [Related]
15. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results. Cerqueira MD; Nguyen P; Staehr P; Underwood SR; Iskandrian AE; JACC Cardiovasc Imaging; 2008 May; 1(3):307-16. PubMed ID: 19356442 [TBL] [Abstract][Full Text] [Related]
16. Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats. Dhalla AK; Wong MY; Wang WQ; Biaggioni I; Belardinelli L J Pharmacol Exp Ther; 2006 Feb; 316(2):695-702. PubMed ID: 16227469 [TBL] [Abstract][Full Text] [Related]
17. Interaction of caffeine with regadenoson-induced hyperemic myocardial blood flow as measured by positron emission tomography: a randomized, double-blind, placebo-controlled crossover trial. Gaemperli O; Schepis T; Koepfli P; Siegrist PT; Fleischman S; Nguyen P; Olmsted A; Wang W; Lieu H; Kaufmann PA J Am Coll Cardiol; 2008 Jan; 51(3):328-9. PubMed ID: 18206744 [No Abstract] [Full Text] [Related]